WO2010127420A9 - Sequências geneticamente modificadas de antígenos de plasmodium vivax - Google Patents

Sequências geneticamente modificadas de antígenos de plasmodium vivax Download PDF

Info

Publication number
WO2010127420A9
WO2010127420A9 PCT/BR2009/000130 BR2009000130W WO2010127420A9 WO 2010127420 A9 WO2010127420 A9 WO 2010127420A9 BR 2009000130 W BR2009000130 W BR 2009000130W WO 2010127420 A9 WO2010127420 A9 WO 2010127420A9
Authority
WO
WIPO (PCT)
Prior art keywords
genetically modified
plasmodium vivax
antigens
dbp
sequences encoding
Prior art date
Application number
PCT/BR2009/000130
Other languages
English (en)
French (fr)
Other versions
WO2010127420A1 (pt
Inventor
Oscar Bruna Romero
Ricardo Tostes Gazzinelli
Marisa Cristina Da Fonseca
Cristiana Ferreira Alves De Brito
Flávio DA FONSECA GUIMARÃES
Cristina Lima Carrara
Leoneide Erica Maduro Bouillet
Maurício MARTINS RODRIGUES
Irene Soares
Bruna De Andrade Pereira
Original Assignee
Universidade Federal De Minas Gerais - Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais - Ufmg filed Critical Universidade Federal De Minas Gerais - Ufmg
Priority to BRPI0924581A priority Critical patent/BRPI0924581A2/pt
Priority to PCT/BR2009/000130 priority patent/WO2010127420A1/pt
Priority to CN2009801603910A priority patent/CN102575256A/zh
Publication of WO2010127420A1 publication Critical patent/WO2010127420A1/pt
Publication of WO2010127420A9 publication Critical patent/WO2010127420A9/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A presente invenção diz respeito à construção de seqϋências genéticas modificadas que compreendem seqϋências para antígenos (DBP-PA, DBP-AM, DBP-MT, AMA-1, CS e MSP-1) de Plasmodium vivax, as respectivas proteínas recombinantes codificadas pelas referidas seqϋências e vírus geneticamente modificados que expressam antígenos recombinantes. Além disso, a presente invenção se refere a um método de vacinação dose-reforço (prime-boost) que utiliza vetores adenovirais ou poxvirais, proteínas purificadas para imunização de mamíferos e composições vacinais ύteis para serem utilizadas como vacina contra malária.
PCT/BR2009/000130 2009-05-05 2009-05-05 Sequências geneticamente modificadas de antígenos de plasmodium vivax WO2010127420A1 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BRPI0924581A BRPI0924581A2 (pt) 2009-05-05 2009-05-05 seqüências geneticamente modificadas de antígenos de plasmodium vivax, composições vacinais contendo proteínas recombinantes e vírus recombinantes que expressam esses antígenos e método de vacinação dose-reforço contra malária
PCT/BR2009/000130 WO2010127420A1 (pt) 2009-05-05 2009-05-05 Sequências geneticamente modificadas de antígenos de plasmodium vivax
CN2009801603910A CN102575256A (zh) 2009-05-05 2009-05-05 编码间日疟原虫抗原的经遗传修饰的序列

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2009/000130 WO2010127420A1 (pt) 2009-05-05 2009-05-05 Sequências geneticamente modificadas de antígenos de plasmodium vivax

Publications (2)

Publication Number Publication Date
WO2010127420A1 WO2010127420A1 (pt) 2010-11-11
WO2010127420A9 true WO2010127420A9 (pt) 2010-12-29

Family

ID=43049863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2009/000130 WO2010127420A1 (pt) 2009-05-05 2009-05-05 Sequências geneticamente modificadas de antígenos de plasmodium vivax

Country Status (3)

Country Link
CN (1) CN102575256A (pt)
BR (1) BRPI0924581A2 (pt)
WO (1) WO2010127420A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231232A1 (en) * 2000-01-31 2001-08-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Centers For Disease Control And Prevention Recombinant multivalent malarial vaccines against plasmodium vivax
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines

Also Published As

Publication number Publication date
WO2010127420A1 (pt) 2010-11-11
BRPI0924581A2 (pt) 2016-07-19
CN102575256A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
WO2007027860A3 (en) Adenoviral vector-based malaria vaccines
IL214460A0 (en) Malaria prime/boost vaccines
JP2016146837A5 (pt)
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
WO2010019262A3 (en) Polyvalent vaccine
MX339830B (es) Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico.
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
WO2015052543A3 (en) Malaria vaccination
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
PH12013501116A1 (en) Raccoon poxvirus expressing rabies glycoproteins
MX2013003238A (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2008086386A8 (en) Adenoviral vector-based malaria vaccines
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
NZ596223A (en) Combined measles-malaria vaccine
WO2010127420A9 (pt) Sequências geneticamente modificadas de antígenos de plasmodium vivax
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2008118936A3 (en) Method of elicting immune response with a modified mva viral hiv-1 vector
MX2010007876A (es) Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
WO2008027414A3 (en) Novel p. falciparum vaccine proteins and coding sequences
WO2011133870A3 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980160391.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09844215

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 9087/DELNP/2011

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 09844215

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0924581

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0924581

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111107